Clinical Trial: Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07327229) titled 'Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma' on Dec. 05, 2025.

Brief Summary: This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Intervention: DRUG: ATG-022

1.8mg/kg Q3W, every 21 days as one cycle ...